Filing Details
- Accession Number:
- 0001641172-25-014002
- Form Type:
- 13G Filing
- Publication Date:
- 2025-06-05 20:00:00
- Filed By:
- Mike Newlin
- Company:
- Fibrobiologics Inc.
- Filing Date:
- 2025-06-06
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
---|---|---|---|
Mike Newlin | 0 | 2,134,853 | 5.579% |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
FibroBiologics, Inc. (Name of Issuer) |
Common Stock, $0.00001 par value (Title of Class of Securities) |
31573L105 (CUSIP Number) |
08/09/2024 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 31573L105 |
1 | Names of Reporting Persons
Mike Newlin | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
TEXAS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,134,853.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.579 % | ||||||||
12 | Type of Reporting Person (See Instructions)
CO, IN |
Comment for Type of Reporting Person: Beneficial ownership percentage based on 38,262,586 shares of the Issuer's common stock, $0.00001 par value per share, issued and outstanding as of May 13, 2025 as disclosed in that certain Quarterly Report on Form 10-Q filed by the Issuer with the U.S. Securities and Exchange Commission on May 14, 2025. Shares of common stock as disclosed herein are held in name of Golden Knight Incorporated, L.P. of which Mike Newlin is the 100% beneficial owner.
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
FibroBiologics, Inc. | |
(b) | Address of issuer's principal executive offices:
455 E. MEDICAL CENTER BLVD, SUITE 300, HOUSTON, TX, 77598 | |
Item 2. | ||
(a) | Name of person filing:
Mike Newlin | |
(b) | Address or principal business office or, if none, residence:
1414 Horseshoe Dr., Sugarland, Texas 77478 | |
(c) | Citizenship:
United States | |
(d) | Title of class of securities:
Common Stock, $0.00001 par value | |
(e) | CUSIP No.:
31573L105 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
2,134,853 | |
(b) | Percent of class:
5.579% | |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
2,134,853 | ||
(ii) Shared power to vote or to direct the vote:
0 | ||
(iii) Sole power to dispose or to direct the disposition of:
2,134,853 | ||
(iv) Shared power to dispose or to direct the disposition of:
0 | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|